Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Torque teno virus | 6 | 2021 | 73 | 1.73 | Why? |
| Plasma | 5 | 2021 | 1809 | 1.43 | Why? |
| Antibodies, Neutralizing | 11 | 2021 | 25288 | 1.14 | Why? |
| DNA, Viral | 7 | 2021 | 2521 | 0.88 | Why? |
| Immunization, Passive | 12 | 2021 | 10067 | 0.83 | Why? |
| DNA Virus Infections | 5 | 2019 | 88 | 0.74 | Why? |
| Transfusion Reaction | 1 | 2021 | 245 | 0.73 | Why? |
| Antibodies, Monoclonal | 4 | 2021 | 8041 | 0.72 | Why? |
| Blood Group Antigens | 1 | 2020 | 202 | 0.70 | Why? |
| Histocompatibility | 1 | 2014 | 53 | 0.55 | Why? |
| Antilymphocyte Serum | 1 | 2014 | 80 | 0.54 | Why? |
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 94 | 0.53 | Why? |
| Neutralization Tests | 4 | 2021 | 6698 | 0.52 | Why? |
| Blood Donors | 3 | 2021 | 2956 | 0.49 | Why? |
| ABO Blood-Group System | 1 | 2021 | 995 | 0.47 | Why? |
| Virus Inactivation | 1 | 2021 | 1139 | 0.46 | Why? |
| Health Communication | 1 | 2021 | 1120 | 0.41 | Why? |
| Convalescence | 1 | 2021 | 2829 | 0.40 | Why? |
| Taste Disorders | 1 | 2020 | 1720 | 0.38 | Why? |
| Antibodies, Viral | 7 | 2021 | 51949 | 0.34 | Why? |
| Transplantation, Homologous | 3 | 2019 | 757 | 0.33 | Why? |
| Nelfinavir | 1 | 2007 | 187 | 0.33 | Why? |
| Antibiotics, Antineoplastic | 1 | 2007 | 128 | 0.32 | Why? |
| Spike Glycoprotein, Coronavirus | 8 | 2021 | 37182 | 0.31 | Why? |
| Toll-Like Receptor 2 | 1 | 2007 | 198 | 0.31 | Why? |
| Pharmaceutical Preparations | 1 | 2020 | 1897 | 0.31 | Why? |
| Real-Time Polymerase Chain Reaction | 4 | 2021 | 11367 | 0.30 | Why? |
| Doxorubicin | 1 | 2007 | 313 | 0.28 | Why? |
| HIV Protease Inhibitors | 1 | 2007 | 434 | 0.26 | Why? |
| Graft Rejection | 1 | 2014 | 1766 | 0.26 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 9335 | 0.25 | Why? |
| Olfaction Disorders | 1 | 2020 | 3704 | 0.24 | Why? |
| Blood Coagulation Factor Inhibitors | 1 | 2021 | 41 | 0.23 | Why? |
| Thyroiditis, Autoimmune | 1 | 2021 | 86 | 0.22 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.22 | Why? |
| Economics, Pharmaceutical | 1 | 2021 | 61 | 0.22 | Why? |
| Hematopoietic Stem Cell Transplantation | 4 | 2019 | 2426 | 0.22 | Why? |
| Immunosuppressive Agents | 2 | 2021 | 6331 | 0.21 | Why? |
| Social Media | 2 | 2021 | 5798 | 0.21 | Why? |
| Viral Vaccines | 1 | 2021 | 7560 | 0.20 | Why? |
| Blood Coagulation Factors | 1 | 2021 | 223 | 0.20 | Why? |
| Hemagglutinins | 1 | 2020 | 143 | 0.20 | Why? |
| Dose-Response Relationship, Immunologic | 1 | 2021 | 593 | 0.19 | Why? |
| Medical Laboratory Personnel | 1 | 2021 | 254 | 0.19 | Why? |
| Humans | 38 | 2021 | 930598 | 0.19 | Why? |
| Liver Transplantation | 1 | 2014 | 2864 | 0.18 | Why? |
| In Vitro Techniques | 1 | 2021 | 1027 | 0.17 | Why? |
| Cardiomyopathies | 1 | 2007 | 997 | 0.17 | Why? |
| DNA Viruses | 1 | 2019 | 184 | 0.17 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2020 | 801 | 0.16 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2020 | 782 | 0.15 | Why? |
| Granulocyte Colony-Stimulating Factor | 1 | 2017 | 264 | 0.15 | Why? |
| Mutation | 5 | 2021 | 12376 | 0.15 | Why? |
| Drug Utilization | 1 | 2020 | 619 | 0.14 | Why? |
| Viremia | 2 | 2019 | 1020 | 0.14 | Why? |
| Extracellular Vesicles | 1 | 2021 | 607 | 0.14 | Why? |
| Glioblastoma | 1 | 2017 | 187 | 0.14 | Why? |
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 290 | 0.14 | Why? |
| Donor Selection | 1 | 2020 | 804 | 0.13 | Why? |
| Communicable Diseases, Imported | 1 | 2021 | 843 | 0.12 | Why? |
| Biological Specimen Banks | 1 | 2020 | 1142 | 0.12 | Why? |
| Ritonavir | 1 | 2007 | 4212 | 0.12 | Why? |
| Infection Control | 1 | 2021 | 23131 | 0.11 | Why? |
| Early Diagnosis | 1 | 2020 | 2443 | 0.11 | Why? |
| Cytomegalovirus Infections | 1 | 2017 | 667 | 0.11 | Why? |
| South Africa | 1 | 2021 | 3326 | 0.11 | Why? |
| Immune Evasion | 1 | 2021 | 2081 | 0.10 | Why? |
| Gene Expression | 1 | 2021 | 3332 | 0.10 | Why? |
| Autoantibodies | 1 | 2021 | 2094 | 0.10 | Why? |
| Cross Reactions | 1 | 2021 | 4374 | 0.10 | Why? |
| Coronavirus Infections | 5 | 2021 | 253789 | 0.10 | Why? |
| Immunocompetence | 2 | 2021 | 280 | 0.09 | Why? |
| Phylogeny | 3 | 2021 | 13341 | 0.09 | Why? |
| Genetic Variation | 1 | 2021 | 3919 | 0.08 | Why? |
| Brazil | 2 | 2021 | 12582 | 0.08 | Why? |
| Treatment Outcome | 3 | 2021 | 51732 | 0.07 | Why? |
| Immunologic Factors | 1 | 2021 | 4206 | 0.07 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.07 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.07 | Why? |
| Italy | 7 | 2021 | 38444 | 0.07 | Why? |
| Information Dissemination | 1 | 2020 | 2986 | 0.07 | Why? |
| Protein Binding | 1 | 2021 | 11430 | 0.07 | Why? |
| Toll-Like Receptor 4 | 1 | 2007 | 390 | 0.07 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2021 | 6153 | 0.06 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| Saliva | 1 | 2018 | 4679 | 0.06 | Why? |
| Malawi | 1 | 2021 | 287 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.05 | Why? |
| Social Medicine | 1 | 2020 | 27 | 0.05 | Why? |
| United Kingdom | 1 | 2021 | 18046 | 0.05 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.05 | Why? |
| Severe Acute Respiratory Syndrome | 2 | 2021 | 12361 | 0.05 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.05 | Why? |
| Male | 10 | 2021 | 367725 | 0.04 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.04 | Why? |
| Fenofibrate | 1 | 2017 | 22 | 0.04 | Why? |
| Dapsone | 1 | 2017 | 59 | 0.04 | Why? |
| Peru | 1 | 2021 | 1010 | 0.04 | Why? |
| Medication Therapy Management | 1 | 2020 | 312 | 0.04 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.04 | Why? |
| Retrospective Studies | 4 | 2021 | 105322 | 0.04 | Why? |
| Bone Marrow Cells | 1 | 2017 | 186 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Pharmacovigilance | 1 | 2020 | 501 | 0.04 | Why? |
| Biomarkers | 1 | 2019 | 23361 | 0.04 | Why? |
| Transplantation Conditioning | 1 | 2017 | 323 | 0.04 | Why? |
| Female | 8 | 2021 | 380317 | 0.04 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.03 | Why? |
| Travel-Related Illness | 1 | 2021 | 1357 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.03 | Why? |
| Travel | 2 | 2021 | 7220 | 0.03 | Why? |
| Risk Factors | 1 | 2021 | 71621 | 0.03 | Why? |
| Immunocompromised Host | 2 | 2019 | 5150 | 0.03 | Why? |
| Child | 1 | 2020 | 70012 | 0.03 | Why? |
| Animals | 1 | 2020 | 78931 | 0.03 | Why? |
| Flow Cytometry | 1 | 2019 | 2393 | 0.03 | Why? |
| Ribavirin | 1 | 2017 | 1182 | 0.02 | Why? |
| Cell Proliferation | 1 | 2017 | 1973 | 0.02 | Why? |
| Carrier State | 1 | 2021 | 2100 | 0.02 | Why? |
| World Health Organization | 1 | 2021 | 4213 | 0.02 | Why? |
| Leukocyte Count | 1 | 2017 | 3178 | 0.02 | Why? |
| Middle Aged | 6 | 2021 | 270681 | 0.02 | Why? |
| Attitude to Health | 1 | 2020 | 2002 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2019 | 4758 | 0.02 | Why? |
| Adult | 5 | 2021 | 244371 | 0.02 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2019 | 11304 | 0.01 | Why? |
| Aged | 4 | 2021 | 215776 | 0.01 | Why? |
| Case-Control Studies | 1 | 2019 | 17671 | 0.01 | Why? |
| Brain | 1 | 2017 | 5133 | 0.01 | Why? |
| Genome, Viral | 1 | 2021 | 13157 | 0.01 | Why? |
| Adolescent | 2 | 2019 | 86841 | 0.01 | Why? |
| Young Adult | 2 | 2019 | 93724 | 0.01 | Why? |
| Prevalence | 1 | 2019 | 25773 | 0.01 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Time Factors | 1 | 2019 | 31397 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| HIV Infections | 1 | 2019 | 11620 | 0.01 | Why? |
| Prospective Studies | 1 | 2018 | 43301 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
Focosi's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(142)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(84)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_